Ozdemir O, et al. - In this retrospective cohort study, researchers compared the impact of 0.0125 mL and 0.025 mL doses of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection on intraocular pressure (IOP) in eyes with aggressive posterior retinopathy of prematurity (ROP). Charts of 52 eyes of 26 consecutive infants have been reviewed. Study participants received 0.0125 mL (Group 1) or 0.025 mL (Group 2) anti-VEGF agents’ intravitreally. This study discovered that IOP rises after intravitreal injections of anti-VEGF agents for the treatment of ROP. In the treatment of infants with aggressive posterior ROP, a 0.025 mL injection of anti-VEGF agents raises IOP more than a 0.0125 mL injection.